GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Short Percentage of Float

Enlivex Therapeutics (Enlivex Therapeutics) Short Percentage of Float


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Enlivex Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Enlivex Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's Short Percentage of Float falls into.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » Short Percentage of Float
Comparable Companies
RGLS CRBP VIRX CRIS ORGS CLRB AGE MRKR CLCS AURX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ENLV:Israel 1BT:Germany
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Website
https://www.enlivex.com
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

By PurpleRose PurpleRose • 08-24-2022

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

By Stock market mentor Stock market mentor • 01-25-2023

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra� to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

By sperokesalga sperokesalga • 02-15-2023

Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial

By sperokesalga sperokesalga • 02-23-2023

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

By sperokesalga sperokesalga • 03-20-2023

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

By Ds*** Ds*** • 08-29-2022

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

By ACCESSWIRE ACCESSWIRE • 04-14-2023

Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update

By Marketwired • 06-26-2023

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

By Value_Insider Value_Insider • 11-15-2022

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra� Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

By PurpleRose PurpleRose • 08-17-2022